President Donald Trump’s attack on drug costs is more likely to deprive Europeans of some medicines rather than lower prices in the US, according to the former boss of Novo Nordisk A/S.
“If the US government succeeds in enforcing the same price globally, then companies will choose the American prices, not the European ones,” Lars Fruergaard Jorgensen said in an interview late Thursday. “And if Europeans refuse to pay the US price, they simply won’t get the product.”
Trump wants US patients to pay the same lower costs for drugs that patients in what he calls “freeloading” nations ...
